基于设备的创新策略,用于管理急性失偿性心力衰竭
Dario Tino Bertolone1, Pasquale Paolisso2, Emanuele Gallinoro3
1Cardiovascular Center Aalst, OLV Hospital, Aalst, Belgium; Department of Advanced Biomedical Sciences, University of Naples, Naples, Italy.
Current problems in cardiology
|August 8, 2023
概括
新型设备为急性不补偿性心力衰竭 (ADHF) 患者提供了新的希望. DRI2P2S分类有助于理解这些创新疗法,尽管需要进一步的研究才能广泛用于临床.
科学领域:
- 心脏病学 心脏病学
- 生物医学工程 生物医学工程
- 医疗器械 医疗器械
背景情况:
- 急性不补偿性心力衰竭 (ADHF) 显著影响老年人,导致高死亡率,发病率和医疗保健费用.
- 目前对ADHF的治疗结果仍然不理想,这凸显了对创新的治疗策略的需求.
- 针对特定病理生理机制的基于设备的干预正在成为一个有希望的途径.
研究的目的:
- 介绍和解释DRI2P2S对心力衰竭新型设备治疗的分类系统.
- 根据其拟议的作用机制对新兴设备进行分类.
- 审查这些设备在ADHF管理中的当前发展状态和未来潜力.
主要方法:
- 这项研究审查和分类了针对ADHF的创新型基于设备的治疗方法.
- 介绍了DRI2P2S分类系统,根据其机制对设备进行分类:扩展器,去除器,异型,间位器,推进器,拉动器和选择性滴水器.
- 讨论了这些设备在急性和慢性心力衰竭设置中的应用.
主要成果:
- DRI2P2S分类为理解各种设备机制提供了一个框架.
- 设备按功能分类,包括增加静脉容量,去除/水,增强收缩性,加速淋巴清除,调节压.
- 大多数新型设备都处于早期发展阶段,需要进行广泛的研究.
结论:
- 基于设备的创新疗法有可能改善ADHF的结果.
- 进一步的研究至关重要,以阐明机制,评估临床疗效,并在日常采用之前确保安全.
- 这些新兴策略可能会彻底改变未来的心力衰竭治疗模式.
相关概念视频
01:30Heart Failure V: Medical Management
13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
01:22Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
01:30Heart Failure VII: Nursing Interventions
94
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
94
01:22Heart Failure Drugs: Diuretics
420
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
420
01:30Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11